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Ayurvedic Research: Scientific
Questions to Address
At the Science Congress we held here in this same Pune
University Campus, Noble laureate Professor Richard
Ernst lectured on work using the latest advances and
tools in high-resolution solid-state NMR, to gain under-
standing of the Chinese system of Acupuncture at the
molecular level. He referred to papers in the Proceedings
of the US National Academy of Science (1). You see,
while western scientists are scientifically probing the
ancient practices of the East, our own Indian research is
invariably focused on the West’s leftover problems. That
is unfortunate: it is a great, great pity indeed.
As I have said, Ayurveda is the ‘Science of Life’. The
period 600 B.C.–800A.D. has been called the ‘Ayurvedic
period’ (2). At that time, developments in Ayurveda led to
fundamental advances in chemistry, and in our ancient
forms of botany and zoology, as well as its own discipline
of medicine. Today, however, Ayurveda gets equated only
with herbal products. That is not only unfortunate, but also
it is just plain wrong. It presents a vision of Ayurveda
through the spectacles of molecular medicine and pharma-
cology, and excludes the greater proportion of its
substantial scientific value. Dravyaguna, Ayurvedic knowl-
edge of herbs, forms only a small part of the whole system.
Similar to the way that Nobel laureate Richard Ernst
was looking at Acupuncture and the science behind it by
probing with high resolution solid-state NMR, much of
Ayurveda requires fundamental physical investigation.
For example, Ayurvedic etiology is couched in terms
of the concept of Dosha Prakriti, as are physician’s
strategies of treatment. It is scientifically very important
to decide whether Prakriti has a genomic basis (3), as
Patwardhan has suggested (3), or if they are only
phenotypes. We are only beginning to address this
question, and future developments may be very
important (4), since establishing a full scientific basis
for Tridosha would be of the utmost significance.
Valiathan also addresses (5) several other similar ques-
tions. If we investigate Panchakarma, that powerful tool
to detoxify the body, does it alter the patient’s biological
and immunological profiles? This has not yet been
investigated. Then there are the Rasayanas. What do they
do? Do they accelerate repair of damaged DNA? Can any
show improvements in mouse models of Alzheimer’s, such
as inhibition of beta-amyloid accumulation? These ques-
tions have not been addressed. There have not been any
studiesonthem;theyarevirginterritorywherewecanmake
major applications and advances.
I would go as far as saying that just as we have cellular
biology, molecular biology and structural biology, there
must be an ‘Ayurvedic biology’ that we should start talking
about. I must give credit to Dr Valiathan for coining this
phrase (5,14). The more I think about it, the more I believe
in it. What has India given to the rest of the world? Did we
give cellular biology, molecular biology or structural bio-
logy? Did we give structural genomics, functional genomics
or pharmacogenomics? No, but we can give Ayurvedic
biology (14) and Ayugenomics (3) to the world alright.
We need to think really seriously about that.
CSIR Involvement: The New Millenium
Indian Leadership Initiative
It makes me very happy to see that systems that used to
be immune to traditional medicine are getting integrated.
As Director General of CSIR, I am very happy that we
have instigated major programs of research. Getting the
program going was very tough. I still remember, Arya
Vaidya Shala, Kottakal, where I went with Dr Warrier to
sign our Memorandum of Understanding, and how,
because of some sort of mutual suspicion, it took us
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properly cited.almost an year to get together. Dr Warrier is a very great
visionary and Dr Valiathan managed to bring us
together. I well remember how, when we had signed the
memorandum, Dr Valiathan said, ‘This is a holy place
for me, because there are two rivers meeting here. One is
the river of traditional knowledge, Arya Vaidya Shala,
and the other is the river of modern knowledge repre-
sented by CSIR’. ‘Sangam’ is the word he used.
I only wondered why it had taken so long for this
‘Sangam’ to take place, but now that it has done so, an
unbelievable program has developed. There are 19 CSIR
laboratories, 21 universities, Arya Vaidya Shala and a
whole range of people working together. It has evolved
into a great program. The CSIR programs include:
 identification of target therapeutic areas
 selection of extracts
 discovery of active fractions
 molecular description of active fractions
 optimization through mixing of fractions
 understanding mechanisms of action
 toxicological studies
 clinical trials
A whole range of things are beginning to happen.
I am particularly happy to recognize the presence here
today of Dr Ashok Vaidya, the Director of SPARC, and
Professor Bhushan Patwardhan, Director of the Univer-
sity of Pune’s Department of Interdisciplinary Health
Sciences. They have both been instrumental in driving the
CSIR Program, which forms part of the ‘New Millennium
Indian Technology Leadership Initiative’ (7). The
program was started at the beginning of the new millen-
nium, hence its name, which means those areas where
India can take a lead—where we have sustainable advant-
age. Ayurveda is one area where we really have sustain-
able advantage, and which we can offer to the world to
fulfil many crucial needs in world medicine (9). Many
scientists have been working on it together. On what?
 establishing the pharmaco-epidemiological evidence
base for Ayurvedic medicines(8)
 the practice and development of standardized herbal
formulations (9)




 hypolipidemic agents (14)
 asthma (15)
 Parkinson’s disease (16)
and many other disorders and the Ayurvedic medicines
prescribed for them.
There has been remarkable progress, and I especially
want to thank Professor Bhushan and Dr Vaidya, and
the others who have been spear-heading this program
that is such a great Indian initiative; something I could
not have talked about 5 years ago, something I could not
have visualized when I was standing here as President
of the Indian Science Congress in the year 2000. At that
time, it had not happened, it did not exist. You see how a
whole movement can take place!
In that science congress I remember my presidential
address (18) on five new proposals, a ‘Panchsheel’, for




 knowledge-centered society and
 innovation-centered India, in that knowledge-
centered society.
In getting it all together, I had had to redefine
knowledge, not just scientific knowledge, but traditional
knowledge and spiritual knowledge as well. On January
3, 2000, it was just a dream, and I am so happy to see the
dream coming true. Vice-Chancellor, what I have found
in my life is that you have to dream. People will call you
crazy. That makes no difference. That is why when all
of us sat together on the 2nd of this month, we were
dreaming about Pune University. All of us must have
that dream, and it will come true. Like myself today, you
will stand here one day, and you will talk about how our
dream came true. Let us keep on dreaming. Our dreams
will come true.
Intellectual Property and Ayurveda
I want to touch on a couple of other points. One is the
issue of intellectual property rights, which will be
discussed in the afternoon. Among the many things this
country can be proud of is the fact that we raised our
voice when our traditional knowledge was being
hypothecated. Wound healing properties of turmeric are
well known. I remember reading about them in the
‘Times of India’ the morning that the news about the
patent was announced. I said to myself, ‘Come on, this
cannot be. My mother knows about it’. That my mother
knew about it was evident to me because right here in
Pune at the National Chemical Laboratory, we were
sitting one evening—me, my wife, my son Ameya and my
mother—when a bird came and fell down. It had suffered
a severe injury, a broken wing. I remember my mother
ran down and made a paste of turmeric powder, ‘haldi’,
and applied it to the bird. The beauty here, by the way, is
that not for a single moment did she think, ‘Will what is
applicable to a human being also be applicable to a bird?’
That is India, alright! I also remember how, when the
bird died after a couple of hours, we all cried as we gave
it a grand burial.
The Times of India article reminded me of that. I said,
‘How come?’ There and then we decided to challenge it.
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of CSIR, which gives me all the freedom in the world, I am
also Secretary to the Government of India, which takes
away all that freedom. So in the evening, with P. N. Haksar
presiding over my lecture, when I announced I was going to
challenge it, I had forgotten my role as secretary. I should
have requested permission because the Department of
Industrial Policy and Promotion was responsible for those
patents. In the end, CSIR decided to fight, and within 14
months we had won the case.
It was no small case, by the way. It was the first time
that a developing nation had protested that you cannot
do such things. Later, we found out why it had
happened: not because US wanted to steal it, NO!! It
was simple. I went and sat in the US patent office and
spent a full day seeing their systems. They showed me
how, when a patent like this is applied for, they search on
the words ‘turmeric’, ‘wound healing’ and ‘powder’, and
see what comes on the screen. What came on the screen?
Nothing. Nothing came on the screen! Why? Because it
was all in our heads, or in some ancient books, to which
they had no access.
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